Weight Loss: In phase III trials, weight loss with the use of exenatide averaged between 0.9 and 2.8 kg over a 30-month time frame, with more weight loss associated when exenatide is added to existing metformin therapy
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al
MTC is a rare thyroid cancer, and while a causative relationship between these medications and MTC has not been proven, MTC did develop in animals at clinically relevant doses during drug development
Understanding how peptides work at the molecular level helps researchers appreciate why the dose schedule follows specific timing
For professional use or clinical inquiries, please contact PLYMOUTH MEDICAL: Citations Nissen, S., & Sharp, R
"But now we're really looking at and are hoping for more information on that financial side." In the meantime, Gudzune said employees, even at smaller companies, could potentially benefit from speaking with the HR representatives about why they don't cover weight loss medication
